A Registry for People With T-cell Lymphoma

Description

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Conditions

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

A Registry for People With T-cell Lymphoma

Condition
T-cell Lymphoma
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope Cancer Center (Data collection only), Duarte, California, United States, 91010

San Diego

UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego, California, United States, 92103

San Francisco

University of California San Francisco (Data collection only), San Francisco, California, United States, 94143

Stanford

Stanford University Medical Center (Data collection only), Stanford, California, United States, 94305-5408

Aurora

University of Colorado (Data Collection Only), Aurora, Colorado, United States, 80045

New Haven

Yale University (Data Collection Only), New Haven, Connecticut, United States, 06511

Miami

University of Miami (Data Collection Only), Miami, Florida, United States, 33136

Tampa

Moffitt Cancer Center (Data Collection Only), Tampa, Florida, United States, 33612

Atlanta

Emory University (Data Collection Only), Atlanta, Georgia, United States, 30322

Chicago

Northwestern Medicine (Data Collection), Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent
  • * Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
  • * Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
  • * T-cell prolymphocytic leukemia
  • * T-cell large granular lymphocytic leukemia
  • * Chronic lymphoproliferative disorder of NK cells
  • * Aggressive NK-cell leukemia
  • * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  • * Chronic active EBV infection of T- and NK-cell type, systemic form
  • * Hydroa vacciniforme-like lymphoproliferative disorder
  • * Adult T-cell leukemia/lymphoma
  • * Extranodal NK/T-cell lymphoma, nasal type
  • * Enteropathy-associated T-cell lymphoma
  • * Monomorphic epitheliotropic intestinal T-cell lymphoma
  • * Intestinal T-cell lymphoma, not otherwise specified (NOS)
  • * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • * Hepatosplenic T-cell lymphoma
  • * Subcutaneous panniculitis-like T-cell lymphoma
  • * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  • * Sézary syndrome
  • * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  • * Primary cutaneous Gamma-Delta T-cell lymphoma
  • * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  • * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  • * Peripheral T-cell lymphoma, not otherwise specified
  • * Angioimmunoblastic T-cell lymphoma
  • * Follicular T-cell lymphoma
  • * Nodal peripheral T-cell lymphoma with TFH phenotype
  • * Anaplastic large cell lymphoma, ALK-positive
  • * Anaplastic large cell lymphoma, ALK-negative
  • * Breast-implant associated anaplastic large cell lymphoma.
  • * NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
  • * Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
  • * Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Steven Horwitz, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2030-07-27